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Oncogenic signaling frequently results in unscheduled overexpression of cell cycle proteins and replicative
stress. In this issue ofCancer Cell, Schvartzman et al. show that inactivation of p53 or pRb inducesMad2, and
the overexpression of this mitotic checkpoint protein is a necessary event during oncogene-induced mitotic
stress.Themitotic checkpoint (also known as the
Spindle Assembly Checkpoint) is amolec-
ular pathway that ensures ordered chro-
mosome segregation, thus preventing
the generation of aneuploid cells with
abnormal chromosome composition (Mu-
sacchio and Salmon, 2007). A critical
component of this pathway is Mad2,
a protein that inhibits the activity of the
anaphase-promoting complex (APC/C).
ACP/C is an E3-ubiquitin ligase that,
when bound to the Cdc20 cofactor,
targets Cyclin B and Securin for degrada-
tion, triggering chromosome segregation
and mitotic exit. Upon incomplete bio-
rientation of chromosomes, Mad2 inhibits
APC/C-Cdc20, thus preventing chromo-
some miss-segregation.
Since the identification of the mitotic
checkpoint, the search for tumor-associ-
ated alterations in the components of
this pathway has been intense. Although
some mutations have been reported
(Pe´rez de Castro et al., 2007), clinical
correlative data were insufficient to
explain the widespread aneuploidy found
in human tumors. These initial negative
results led to the hypothesis that this
molecular pathway may not be involved
in tumor development. However, further
work with cultured cells and genetically
engineered mice provided some new
insights on the relevance of the mitotic
checkpoint in preventing aneuploidy.
The pioneer analysis of mutant mice
partially deficient inMad2 showedacorre-
lation between the presence of chromo-
somal instability and the development of
lung tumors (Michel et al., 2001).
However, Mad2 is not downregulated in
human tumors, but is rather overex-
pressed as part of a transcriptional signa-
ture commonly found in chromosomallyunstable tumors (Pe´rez de Castro et al.,
2007). Further work identified Mad2 as
an E2F-target gene linking the inactivation
of the retinoblastoma (pRb) protein with
Mad2 overexpression (Hernando et al.,
2004) (Figure 1). Overexpression of
Mad2 was then shown to generate chro-
mosomal instability and to favor tumor
development in vivo (Sotillo et al., 2007).
Since E2F transcription factors induce
multiple mitotic genes and Mad2 may
have additional nonmitotic functions, it
was not clear to what extent Mad2 was
merely a marker of E2F deregulation or
responsible for the chromosomal insta-
bility induced by the loss of pRb or other
tumor suppressors.
In a study published in this issue of
Cancer Cell, Schvartzman et al. (2011)
show that upregulation of Mad2 is neces-
sary for the aneuploidy induced upon
inactivation of not only pRb but also p53
in tumor cells. Since all three pocket
proteins—pRb, p107, and p130—may
repress Mad2, Schvartzman et al. studied
chromosomal instability in cells deficient
in these three proteins. These triple
mutant cells displayed a significant over-
expression of Mad2 as well as BubR1,
another component of the mitotic check-
point. Specific normalization of Mad2
levels, using lentiviral vectors expressing
specific short-hairpin interference RNAs,
had no significant effect on cell prolifera-
tion but rescued chromosomal instability
in these mutant cells. Similarly, Mad2 was
overexpressed in mammary gland adeno-
carcinomas induced by the inhibition of
pRb family members using the T121 frag-
ment from the SV40 large T antigen.
Schvartzman et al. reduced Mad2 levels
close towild-type levels by crossing these
transgenic mice with Mad2(+/) hetero-Cancer Cellzygous mutants. Normalization of Mad2
levels resulted in more differentiated
tumors and a dramatic decrease in
anaplastic neoplasias, a tumor type char-
acterized by high levels of aneuploidy
(Schvartzman et al., 2011).
Inactivation of p53 is also known to
induce chromosomal instability as
a consequence of defective p21Cip1 func-
tion. Knockin mice in which the wild-type
p53 alleles have been replaced by
p53R172P, a p53 mutant that does not
induce apoptosis but is competent in
inducing p21Cip1, developed lymphomas
and sarcomas with stable diploid
genomes. These tumors became aneu-
ploid in a p21Cip1-deficient background,
suggesting that this CDK inhibitor is
necessary for preventing chromosomal
instability downstream of p53 (Barboza
et al., 2006). Interestingly, p21Cip1-defi-
cient mice harboring p53R172P alleles
overexpressed Mad2 and normalization
of Mad2 levels using a Mad2(+/) back-
ground also rescued chromosomal insta-
bility in these animals (Schvartzman et al.,
2011). These elegant genetic data estab-
lish the relevance of the p53-p21Cip1-
Mad2 pathway in the control of the
integrity of the genome. p53 is likely to
repressMad2 through the p21Cip1-depen-
dent inhibition of cyclin-dependent
kinases (CDKs) and the subsequent acti-
vation of pRb. Given the known regulation
of Mad2 by the pRb-E2F axis, these data
establish a major role for the two major
tumor suppressor molecules, p53 and
pRb, in controlling genomic integrity
through the E2F-dependent transcrip-
tional regulation of Mad2 (Figure 1).
The widespread aneuploidy seen in
human tumors has been frequently used
to support a possible causal role of19, June 14, 2011 ª2011 Elsevier Inc. 691
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Figure 1. Oncogene-Induced Replicative and Mitotic Stress
In normal cells, pRb family members and p53 control the expression of critical regulators of DNA replica-
tion and mitosis, in part by regulating the activity of the E2F family transcription factors. Mad2 is one of the
E2F targets involved in the mitotic checkpoint that controls chromosome segregation. Oncogenic alter-
ations resulting in the inactivation of these major tumor suppressor pathways lead to deregulated E2F
activity and the overexpression of multiple genes required for the G1/S transition. This results in replicative
stress and eventually unscheduled cell cycle progression. In these conditions, several mitotic genes
including Mad2 are also overexpressed, resulting in mitotic stress. The overexpression of Mad2 leads
to deregulation of themitotic checkpoint and aberrant chromosome segregation. NormalizingMad2 levels
in p53- or pRb-deficient mice rescues aneuploidy suggesting that Mad2 is a necessary target of these
proteins to suppress chromosomal instability.
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Previewschromosomal instability in tumor forma-
tion. However, aneuploidy has clear anti-
proliferative effects, and the debate on
its oncogenic or tumor suppression func-
tion is still open (Holland and Cleveland,
2009). How is it possible that most human
tumors are aneuploid? Since virtually all
human tumors display deficient p53 or
pRb pathways, Mad2 upregulation is
possibly a common event during specific
stages of malignant transformation. This
upregulation likely causes a mitotic stress
that parallels the replicative stress caused
by oncogenic signaling (Halazonetis et al.,
2008); we propose here to use the term
‘‘oncogene-induced mitotic stress’’ to
define this state (Figure 1). Similar to the
defective DNA replication observed in692 Cancer Cell 19, June 14, 2011 ª2011 Elsthe presence of replicative stress, the
mitotic stress would have antiproliferative
effects as a consequence of abnormal
chromosome segregation. The frequent
aneuploidy observed in human tumors
may remain in some cases as a fingerprint
of this original chromosomal instability.
However, the fact that, despite the initial
chromosomal instability generated by
loss of these tumor suppressors, many
cancers maintain relatively stable
genomes (either diploid or aneuploid)
actually favors the idea that chromosomal
instability is initially detrimental for tumor
development. The tumor cells may either
downregulate Mad2 or, alternatively,
acquire additional alterations (perhaps
overexpression of Cdc20) (Pe´rez de Cas-evier Inc.tro et al., 2007) to counteract the adverse
effects of high levels of Mad2. Other
tumors manage to survive with high levels
of chromosomal instability, and this alter-
ation usually correlates with poor prog-
nosis. How these tumor cells deal with
the adverse effects of this continuous
instability is a major question to be solved
in the future. Fortunately, chromosomal
instability and aneuploidy can also be ex-
ploited for cancer therapy (Manchado and
Malumbres, 2011), and p53- or pRb-defi-
cient cells can eventually become a selec-
tive target for such treatments. The
requirements for Mad2 in oncogene-
induced mitotic stress may provide the
first molecular clue to translate the inacti-
vation of tumor suppressors into a lethal
strategy against tumor cells.REFERENCES
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